Curie Therapeutics
Manufacturing · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
2f Gill St, Woburn, Massachusetts, 01801...Website
www.curietherapeutics.comRevenue
$5.1 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Curie Therapeutics
Curie Therapeutics is a fully integrated, next-generation radiopharmaceuticals company focused on pioneering a new class of targeted radiopharmaceuticals that are both safe and effective. Curie's radiopharmaceuticals are composed of rationally designed conjugates against carefully selected biological targets, to deliver alpha and beta-emitting radionuclide payloads. Curie's mission is to revolutionize the use of radiomedicines in cancer.Explore more
Curie Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Curie Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Curie Therapeutics launches new products
Click to see if Curie Therapeutics had a recent Job posting/layoffs
Curie Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Curie Therapeutics recently announced quarterly report
Check if Curie Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Check out if Curie Therapeutics is spiking on competitors!
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Curie Therapeutics
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Curie Therapeutics has new funding data
Recommended Actions
Find VP level buyers at Curie Therapeutics
Find more new buyers
Compare Similar Companies to Curie Therapeutics
Compare insights from companies similar to Curie Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Curie Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Curie Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Curie Therapeutics.
Curie Therapeutics financials insights
Gather financial insights about Curie Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Series A
$75M
Curie Therapeutics Tech Stack
A closer look at the technologies used by Curie Therapeutics
See more technologies
Most Recent Scoops
Promotion
Executive Move
Georgette Verdin has been promoted to the role of Chief People Officer.
New Hire
Executive Move
New Hire
Executive Move
Curie Therapeutics has announced that Bernard Lambert has joined the company to serve as the Chief Technology Officer. Previously, Lambert served as the President & Cheif Operating Officer (US) for Telix Pharmaceuticals.
New Hire
Funding
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Curie Therapeutics
Sign Up For FreeTo access detailed company insights
Curie Therapeutics is a fully integrated, next-generation radiopharmaceuticals company focused on pioneering a new class of targeted radiopharmaceuticals that are both safe and effective. Curie's radiopharmaceuticals are composed of rationally designed conjugates against carefully selected biological targets, to deliver alpha and beta-emitting radi... Read More
